.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

Improving Clinical Outcomes in NSCLC

EP. 1: Introduction: Checkpoint Inhibition in NSCLC

February 7th 2014

EP. 2: Checkpoint Inhibitor Related Pseudoprogression in NSCLC

February 7th 2014

EP. 3: Immune Checkpoint Inhibitor Combinations in NSCLC

February 7th 2014

EP. 4: Current Status of Immunotherapy in NSCLC

February 7th 2014

EP. 5: Second-Generation ALK Inhibitors in NSCLC

February 7th 2014

EP. 6: Development of ALK Inhibitors in Advanced NSCLC

February 7th 2014

EP. 7: Next-Generation Targeted Therapies in NSCLC

February 7th 2014

EP. 8: Adjuvant EGFR Inhibition in Patients With NSCLC

February 7th 2014

EP. 9: Optimizing Maintenance Therapy in NSCLC

February 7th 2014

EP. 10: Maintenance Therapy in Non-Small Cell Lung Cancer

February 7th 2014

EP. 11: Determining When to Administer Maintenance Therapy in NSCLC

February 7th 2014

EP. 12: Next-Generation Sequencing in Lung Cancer

February 7th 2014

EP. 13: Skeletal-Related Event Management in Lung Cancer

February 7th 2014

EP. 14: Final Thoughts on Improving Outcomes in NSCLC

February 7th 2014